$5–$10 is absurd. DCVax works, targeting all tumor-based cancers, is highly scalable, and is extensively protected by patents.
Meanwhile, Merck's Keytruda, which accounts for 46% of the company's total revenue, faces patent expiration in 2028. Currently, four Keytruda biosimilars exist, with three in phase 3 trials. A partnership with DCVax—pending its approval and validation—could prevent catastrophe for any company involved. While there are numerous PD-L1 inhibitors, DCVax stands alone, fortified by robust patent protection. Whether through a partnership or a likely buyout, Merck will inevitably pay far more than $10.
Market Data 
Markets 
AI
